TITLE

Pharmacotherapy of Obesity: An Update

AUTHOR(S)
Schurgin, Sunita; Siegel, Richard D.
PUB. DATE
January 2003
SOURCE
Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for chronic weight loss and maintenance, sibutramine and orlistat. This article reviews these medications and others currently being used for weight loss and weight maintenance. Available medications for obesity include drugs that affect caloric intake and appetite and alter energy expenditure and nutrient absorption, as well as some with an unclear mechanism of action at present. Dozens of drugs in different phases of clinical investigation could be available in the next decade.
ACCESSION #
22450577

 

Related Articles

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons. Kanaya, Alka M. // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p24 

    The article focuses on 30 randomized controlled trials (RCTs) investigating the long-term efficacy of antiobesity drugs (AODs) for reducing weight and improving health status in overweight or obese persons. Trials found out that orlistat, sibutramine and rimonabant reduces weight and improve...

  • NICE gives go-ahead for rimonabant.  // Pulse;7/9/2008, Vol. 68 Issue 24, p18 

    The article reports on the approval of the use of rimonabant in obese patients who cannot take orlistat and sibutramine by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. The institute has advised that there must be careful consideration of current or previous...

  • New drug policy in childhood obesity. Molnár, D. // International Journal of Obesity;Sep2005 Supplement 2, Vol. 29, pS62 

    OBJECTIVE:To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.METHODS:The paper reviews current and investigational antiobesity drugs.RESULTS:At present, there are only few drugs approved by the Food and Drug...

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • Study Shows Weight Loss Program with Xenical Can Also Help Lower Blood Pressure in Obese Hypertensive Patients.  // Ascribe Newswire: Medicine;11/13/2000, p5 

    The article cites a study by researchers at the University of Alabama at Birmingham, Alabama, which holds that weight loss program with xenical can help in lowering blood pressure in obese hypertension patients. Results from a multicoated clinical trial show that weight loss induced by xenical...

  • The Management of Hypertension in the Overweight and Obese Patient: Is Weight Reduction Sufficient? Douketis, James D.; Sharma, Arya M. // Drugs;2004, Vol. 64 Issue 8, p795 

    The management of hypertension in the overweight and obese patient is a frequently encountered but under investigated clinical problem. The conventional management of such patients involves weight reduction with dietary therapy or a combined approach with dietary and anti-obesity drug therapy....

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics